Should I Buy ADCT? ADCT 2026 Analysis

Should You Buy ADC Therapeutics SA (ADCT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.880

1 Day change

1.67%

52 Week Range

4.980

Analysis Updated At

2026/03/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ADC Therapeutics SA (ADCT) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks clear positive momentum, has weak financial performance, and no significant trading signals or catalysts to justify immediate investment. Holding off for now is advisable.

Technical Analysis

The stock shows mixed technical signals. While moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 52.647, and the price is near a key support level (S1: 3.992).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

The FDA and European Commission approvals for ZYNLONTA as a treatment for diffuse large B-cell lymphoma provide a positive long-term catalyst for the company.

Neutral/Negative Catalysts

Additionally, the press release warns of risks and uncertainties that could impact future results.

Financial Performance

In Q3 2025, revenue dropped by -11.03% YoY to $16.43M, net income fell by -6.83% YoY to -$40.97M, EPS declined by -14.29% YoY to -0.36, and gross margin decreased by -2.84% YoY to 92.68%. Overall, the financials show a weakening trend.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes are available for ADCT.

3 Analyst Rating

Wall Street analysts forecast ADCT stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 4.800

Low

Averages

7.33

High

Current: 4.800

Low

Averages

7.33

High

H.C. Wainwright

Robert Burns

Buy

downgrade

$8 -> $7

AI Analysis

2025-10-16

Reason

H.C. Wainwright

Robert Burns

Price Target

$8 -> $7

AI Analysis

2025-10-16

downgrade

Buy

Reason

H.C. Wainwright analyst Robert Burns lowered the firm's price target on ADC Therapeutics to $7 from $8 and keeps a Buy rating on the shares. The firm reduced the price target after factoring in the private placement financing.

RBC Capital

Gregory Renza

Outperform

downgrade

$8 -> $5

2025-06-21

Reason

RBC Capital

Gregory Renza

Price Target

$8 -> $5

2025-06-21

downgrade

Outperform

Reason

RBC Capital analyst Gregory Renza lowered the firm's price target on ADC Therapeutics to $5 from $8 but keeps an Outperform rating on the shares. The firm says the company's high efficacy for Zynlonta in DLBCL gives it confidence in its likelihood to show clinically meaningful benefits in the 2nd line LOTIS-5 study, unlocking an additional $200M+ U.S. sales opportunity, the analyst tells investors in a research note. RBC adds that ADC shares are undervalued on the balance of a largely de-risked asset with multiple expansion opportunities that can reaccelerate growth.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ADCT

Unlock Now

ADCT Should I Buy

ADCT Should I Buy

Should You Buy ADC Therapeutics SA (ADCT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch